-news and infos- 


Radiohybrid PSMA-targeted Agents for Prostate Cancer licensed to Blue Earth Diagnostics

MUNICH, May 2018 – SCINTOMICS has signed an exclusive, worldwide agreement with Blue Earth Diagnostics, a leading molecular imaging diagnostics company. Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.
Read more

FAQ: Can we establish F-18-Radiohybrid-PSMA in our hospital ?

YES, you can !
If you like to exploit the outstanding features of the F-18 or Ga-68-Radiohybrid PSMA inhibitors in your hospital press the ´read more´ bottom below or contact or give us a call. Read more

AVAILABLE: Precursor for Lu-177 PSMA Therapy

Lu-177-PSMA Precursor on stock.

Selected References:

1. Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, Wester HJ, Baum RP. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
J Nucl Med. 2016 Oct;57(Suppl 3):97S-104S. Review.

2. Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL.J Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy.
Nucl Med 2017; 58:67S–76S; Review

3. Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand Therapy for Prostate Cancer.
J Nucl Med 2017; 58:1196–1200

4. Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
J Nucl Med. 2016 Jul;57(7):1006-13.
Read more

AGRR 2018

20.-22.09.2018 Aachen(Germany)


13.-17.10.2017 Düsseldorf(Germany)